Masimo (NASDAQ:MASI) updated its FY18 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of $2.80 for the period, compared to the Thomson Reuters consensus estimate of $2.66. The company issued revenue guidance of $836.0 million, compared to the consensus revenue estimate of $832.07 million.
Several brokerages recently issued reports on MASI. Barclays began coverage on shares of Masimo in a research note on Friday, March 9th. They issued an overweight rating and a $97.00 price target for the company. Zacks Investment Research upgraded shares of Masimo from a hold rating to a buy rating and set a $94.00 price target for the company in a research note on Tuesday, March 6th. Piper Jaffray Companies reiterated a hold rating and issued a $91.00 price target on shares of Masimo in a research note on Thursday, March 1st. Finally, BidaskClub upgraded shares of Masimo from a sell rating to a hold rating in a research note on Thursday, March 1st. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Masimo presently has a consensus rating of Buy and an average target price of $101.00.
Shares of Masimo (NASDAQ MASI) traded down $1.58 during mid-day trading on Wednesday, reaching $87.86. 545,327 shares of the company traded hands, compared to its average volume of 595,392. Masimo has a one year low of $80.69 and a one year high of $104.71. The stock has a market cap of $4,580.00, a P/E ratio of 27.95, a price-to-earnings-growth ratio of 2.34 and a beta of 0.91.
Masimo (NASDAQ:MASI) last announced its quarterly earnings data on Tuesday, February 27th. The medical equipment provider reported $0.72 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.61 by $0.11. Masimo had a net margin of 16.49% and a return on equity of 22.75%. The company had revenue of $225.20 million for the quarter, compared to the consensus estimate of $201.54 million. During the same period in the prior year, the firm posted $0.46 EPS. Masimo’s revenue for the quarter was up 22.9% on a year-over-year basis. analysts forecast that Masimo will post 2.81 EPS for the current fiscal year.
In other news, EVP Yongsam Lee sold 10,000 shares of the firm’s stock in a transaction dated Friday, January 5th. The shares were sold at an average price of $88.17, for a total transaction of $881,700.00. Following the sale, the executive vice president now owns 75,018 shares of the company’s stock, valued at approximately $6,614,337.06. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Sanford Fitch sold 2,000 shares of the firm’s stock in a transaction dated Thursday, January 25th. The shares were sold at an average price of $90.00, for a total transaction of $180,000.00. Following the sale, the director now directly owns 70,249 shares in the company, valued at approximately $6,322,410. The disclosure for this sale can be found here. Insiders have sold a total of 24,000 shares of company stock worth $2,177,340 over the last three months. 13.10% of the stock is currently owned by insiders.
TRADEMARK VIOLATION WARNING: “Masimo (MASI) Issues FY18 Earnings Guidance” was originally published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this news story on another site, it was illegally stolen and republished in violation of United States & international trademark and copyright laws. The original version of this news story can be viewed at https://ledgergazette.com/2018/03/14/masimo-masi-updates-fy18-earnings-guidance.html.
Masimo Company Profile
Masimo Corporation is a medical technology company that develops, manufactures and markets a range of non-invasive patient monitoring technologies. The Company’s business is Measure-through Motion and Low Perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry.
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.